Meg Keilman

1.3k total citations · 1 hit paper
12 papers, 1.1k citations indexed

About

Meg Keilman is a scholar working on Infectious Diseases, Hepatology and Molecular Biology. According to data from OpenAlex, Meg Keilman has authored 12 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Infectious Diseases, 9 papers in Hepatology and 6 papers in Molecular Biology. Recurrent topics in Meg Keilman's work include HIV/AIDS drug development and treatment (10 papers), Hepatitis C virus research (9 papers) and Biochemical and Molecular Research (4 papers). Meg Keilman is often cited by papers focused on HIV/AIDS drug development and treatment (10 papers), Hepatitis C virus research (9 papers) and Biochemical and Molecular Research (4 papers). Meg Keilman collaborates with scholars based in United States. Meg Keilman's co-authors include Angela M. Lam, Phillip A. Furman, Michaël Otto, Shalini Bansal, Holly M. Micolochick Steuer, Christine Espiritu, Congrong Niu, Michael J. Sofia, Wonsuk Chang and Bruce S. Ross and has published in prestigious journals such as Journal of Medicinal Chemistry, Antimicrobial Agents and Chemotherapy and Journal of Hepatology.

In The Last Decade

Meg Keilman

12 papers receiving 986 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus

2010 486 citations Michael J. Sofia, Donghui Bao et al. Journal of Medicinal Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Meg Keilman United States	9	609	522	482	319	181	12	1.1k
Shalini Bansal United States	14	710 1.2×	654 1.3×	609 1.3×	440 1.4×	224 1.2×	29	1.4k
Donghui Bao United States	10	425 0.7×	463 0.9×	342 0.7×	361 1.1×	178 1.0×	17	963
Holly M. Micolochick Steuer United States	16	957 1.6×	845 1.6×	811 1.7×	489 1.5×	202 1.1×	27	1.6k
Bruce S. Ross United States	17	551 0.9×	644 1.2×	452 0.9×	762 2.4×	351 1.9×	42	1.6k
Christine Espiritu United States	17	1.1k 1.9×	810 1.6×	1.0k 2.1×	502 1.6×	163 0.9×	34	1.8k
Hai‐Ren Zhang United States	13	330 0.5×	409 0.8×	273 0.6×	368 1.2×	398 2.2×	16	1.0k
Makonen Belema United States	13	749 1.2×	322 0.6×	558 1.2×	280 0.9×	292 1.6×	18	1.2k
Sonal Rajyaguru United States	18	728 1.2×	589 1.1×	550 1.1×	272 0.9×	191 1.1×	25	1.1k
Phillip M. Tharnish United States	17	420 0.7×	721 1.4×	404 0.8×	460 1.4×	373 2.1×	30	1.3k
Sylvie Goulet Canada	16	510 0.8×	351 0.7×	290 0.6×	256 0.8×	292 1.6×	20	939

Countries citing papers authored by Meg Keilman

Since Specialization

Citations

This map shows the geographic impact of Meg Keilman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meg Keilman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meg Keilman more than expected).

Fields of papers citing papers by Meg Keilman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meg Keilman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meg Keilman. The network helps show where Meg Keilman may publish in the future.

Co-authorship network of co-authors of Meg Keilman

This figure shows the co-authorship network connecting the top 25 collaborators of Meg Keilman. A scholar is included among the top collaborators of Meg Keilman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meg Keilman. Meg Keilman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Kakarla, Ramesh, Jian Liu, Devan Naduthambi, et al.. (2014). Discovery of a Novel Class of Potent HCV NS4B Inhibitors: SAR Studies on Piperazinone Derivatives. Journal of Medicinal Chemistry. 57(5). 2136–2160. 43 indexed citations

Chang, Wonsuk, Ralph T. Mosley, Shalini Bansal, et al.. (2012). Inhibition of hepatitis C virus NS5A by fluoro-olefin based γ-turn mimetics. Bioorganic & Medicinal Chemistry Letters. 22(8). 2938–2942. 52 indexed citations

Lam, Angela M., Christine Espiritu, Shalini Bansal, et al.. (2012). Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus. Antimicrobial Agents and Chemotherapy. 56(6). 3359–3368. 202 indexed citations

Wang, Peiyuan, Suguna Rachakonda, Véronique Zennou, et al.. (2012). Phosphoramidate Prodrugs of (−)-β-D-(2R,4R)-dioxolane-thymine (DOT) as Potent Anti-HIV Agents. Antiviral chemistry & chemotherapy. 22(5). 217–238. 8 indexed citations

Furman, Phillip A., Eisuke Murakami, Congrong Niu, et al.. (2011). Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661. Antiviral Research. 91(2). 120–132. 36 indexed citations

Du, Jinfa, Hai‐Ren Zhang, Wonsuk Chang, et al.. (2011). Synthesis of Stable Isotope Labeled Analogs of the Anti-Hepatitis C Virus Nucleotide Prodrugs PSI-7977 and PSI-352938. Nucleosides Nucleotides & Nucleic Acids. 30(11). 886–896. 3 indexed citations

Lam, Angela M., Christine Espiritu, Eisuke Murakami, et al.. (2011). Inhibition of Hepatitis C Virus Replicon RNA Synthesis by PSI-352938, a Cyclic Phosphate Prodrug of β-d-2′-Deoxy-2′-α-Fluoro-2′-β-C-Methylguanosine. Antimicrobial Agents and Chemotherapy. 55(6). 2566–2575. 29 indexed citations

Reddy, P. Ganapati, Donghui Bao, Wonsuk Chang, et al.. (2010). 2′-Deoxy-2′-α-fluoro-2′-β-C-methyl 3′,5′-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: Discovery of PSI-352938. Bioorganic & Medicinal Chemistry Letters. 20(24). 7376–7380. 43 indexed citations

Zennou, Véronique, Angela M. Lam, Meg Keilman, et al.. (2010). 1034 COMBINATION OF TWO COMPLEMENTARY NUCLEOTIDE ANALOGUES PSI-7977 AND PSI-938 EFFECTIVELY CLEARS WILD TYPE AND NS5B:S282T HCV REPLICONS – COMPARISON WITH COMBINATIONS OF OTHER ANTIVIRAL COMPOUNDS. Journal of Hepatology. 52. S400–S401. 7 indexed citations

10.

Chang, Wonsuk, Donghui Bao, Devan Naduthambi, et al.. (2010). Discovery of PSI-353661, a Novel Purine Nucleotide Prodrug for the Treatment of HCV Infection. ACS Medicinal Chemistry Letters. 2(2). 130–135. 37 indexed citations

11.

Lam, Angela M., Eisuke Murakami, Christine Espiritu, et al.. (2010). PSI-7851, a Pronucleotide of β- d -2′-Deoxy-2′-Fluoro-2′- C -Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication. Antimicrobial Agents and Chemotherapy. 54(8). 3187–3196. 105 indexed citations

12.

Sofia, Michael J., Donghui Bao, Wonsuk Chang, et al.. (2010). Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus. Journal of Medicinal Chemistry. 53(19). 7202–7218. 486 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact